NO982055D0 - 2-alkylpyrrolidiner - Google Patents

2-alkylpyrrolidiner

Info

Publication number
NO982055D0
NO982055D0 NO982055A NO982055A NO982055D0 NO 982055 D0 NO982055 D0 NO 982055D0 NO 982055 A NO982055 A NO 982055A NO 982055 A NO982055 A NO 982055A NO 982055 D0 NO982055 D0 NO 982055D0
Authority
NO
Norway
Prior art keywords
alkylpyrrolidine
methylpyrrolidines
hydroxymethylpyrrolidine
dihydroxy
diabetes
Prior art date
Application number
NO982055A
Other languages
English (en)
Norwegian (no)
Other versions
NO982055L (no
Inventor
Karsten Lundgren
Palle Jakobsen
Marit Kristiansen
Leif Naerskov-Lauritsen
Lars Naerum
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO982055L publication Critical patent/NO982055L/no
Publication of NO982055D0 publication Critical patent/NO982055D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
NO982055A 1995-09-08 1998-05-06 2-alkylpyrrolidiner NO982055D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK99295 1995-09-08
PCT/DK1996/000373 WO1997009040A1 (fr) 1995-09-08 1996-09-06 2-alkylpyrrolidines

Publications (2)

Publication Number Publication Date
NO982055L NO982055L (no) 1998-05-06
NO982055D0 true NO982055D0 (no) 1998-05-06

Family

ID=8099807

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982055A NO982055D0 (no) 1995-09-08 1998-05-06 2-alkylpyrrolidiner

Country Status (12)

Country Link
US (2) US5854272A (fr)
EP (3) EP0858335B1 (fr)
JP (2) JP3043430B2 (fr)
CN (1) CN1202105A (fr)
AT (1) ATE234092T1 (fr)
AU (1) AU724003B2 (fr)
CZ (1) CZ120398A3 (fr)
DE (1) DE69626660T2 (fr)
HU (1) HUP9901132A2 (fr)
IL (1) IL124109A (fr)
NO (1) NO982055D0 (fr)
WO (1) WO1997009040A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9901132A2 (hu) * 1995-09-08 1999-07-28 Novo Nordisk A/S 2-Alkilpirrolidinek
US5952363A (en) * 1997-03-04 1999-09-14 Novo Nordisk A/S Pyrrolidine compounds useful in the treatment of diabetes
AU6291098A (en) * 1997-03-07 1998-09-29 Novo Nordisk A/S Novel heterocyclic compounds
EP1150674A1 (fr) * 1999-02-12 2001-11-07 Novo Nordisk A/S Utilisation de derives de pyrrolidine pour la preparation d'une composition pharmaceutique destinee au traitement ou a la prevention de l'obesite ou a la regulation de l'appetit
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
WO2000055132A1 (fr) * 1999-03-15 2000-09-21 Novo Nordisk A/S Nouveau sel de (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6316489B1 (en) * 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
JP2002539194A (ja) * 1999-03-15 2002-11-19 ノボ ノルディスク アクティーゼルスカブ 新規の（２ｒ，３ｒ，４ｒ）−３，４−ジヒドロキシ−２−ヒドロキシメチルピロリジンの塩
WO2001068095A1 (fr) * 1999-05-24 2001-09-20 Abaron Biosciences, Inc. Inhibiteurs de glycosyltransferase
US6043091A (en) * 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6414163B1 (en) * 2000-08-02 2002-07-02 Board Of Trustees Of Michigan State University Process and intermediate compounds for the preparation of pyrrolidines
CN100506807C (zh) 2001-12-21 2009-07-01 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
JP2006507359A (ja) * 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー／エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
EP1625112B1 (fr) 2003-05-14 2009-07-22 High Point Pharmaceuticals, LLC Nouveaux composes pour le traitement de l'obesite
JP4486792B2 (ja) * 2003-06-12 2010-06-23 学校法人近畿大学 環状オニウム化合物およびグルコシダーゼ阻害剤
CA2539596A1 (fr) 2003-09-30 2005-04-07 Kilian Waldemar Conde-Frieboes Nouveaux agonistes du recepteur de la melanocortine
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
WO2005066145A1 (fr) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-urees et leur utilisation en tant qu'activateurs de glucokinase
JP2007536344A (ja) 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
EP1758575A1 (fr) 2004-06-11 2007-03-07 Novo Nordisk A/S Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
EP1824835A1 (fr) 2004-12-03 2007-08-29 Novo Nordisk A/S Composes heteroaromatiques activants de glukokinase
KR100696187B1 (ko) 2005-05-03 2007-03-20 (주)리드젠 2-(2-아미노에틸)-1-메틸피롤리딘의 제조방법
WO2007006814A1 (fr) 2005-07-14 2007-01-18 Novo Nordisk A/S Activateurs de l'uree glucokinase
US7915299B2 (en) 2006-11-15 2011-03-29 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
WO2010049678A2 (fr) * 2008-10-31 2010-05-06 Summit Corporation Plc Traitement de maladies utilisant de l’énergie
JP5645137B2 (ja) * 2009-11-11 2014-12-24 国立大学法人富山大学 食後過血糖改善剤、およびピロリジン型イミノ糖またはその塩
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
AU2011231503C1 (en) 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
KR101979036B1 (ko) 2010-12-23 2019-05-15 알렉토스 테라퓨틱스 인크. 선택적인 글리코시다아제 저해제 및 이의 용도
BR112013024076A2 (pt) 2011-03-28 2016-12-06 Novo Nordisk As análogos de glucagon
US9718854B2 (en) 2011-03-31 2017-08-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000086A1 (fr) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Inhibiteurs de glycosidases sélectifs et leurs utilisations
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
MY188344A (en) 2012-03-09 2021-12-01 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
US9809537B2 (en) 2012-08-31 2017-11-07 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
RU2672873C2 (ru) 2012-10-31 2018-11-20 Алектос Терапьютикс Инк. Ингибиторы гликозидаз и их применения
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
EP3151852A1 (fr) 2014-06-04 2017-04-12 Novo Nordisk A/S Co-agonistes de récepteur du glucagon/glp-1 à usage médical
CN106349141B (zh) * 2016-08-30 2020-10-27 中国科学院化学研究所 多羟基吡咯烷类化合物及其制备方法和应用
CN111032680A (zh) 2017-03-15 2020-04-17 诺和诺德股份有限公司 能够与黑皮质素4受体结合的双环化合物
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1602744A (fr) 1968-02-16 1971-01-18
JPS5346967A (en) 1976-10-08 1978-04-27 Kyowa Hakko Kogyo Co Ltd R-2-(beta-halogenoethyl)-1-methyl-pyrrolidine
JPS6058749B2 (ja) 1978-02-09 1985-12-21 日清製粉株式会社 光学活性ｎ‐メチル‐２‐ピロリジンエタノ−ルの製造法
JPS61118360A (ja) 1984-11-13 1986-06-05 Mitsubishi Chem Ind Ltd ピロリジン誘導体またはその塩
US4999360A (en) * 1987-12-21 1991-03-12 Monsanto Company Method of inhibiting virus
ES2086323T3 (es) * 1988-11-03 1996-07-01 Searle & Co Derivados del didesoxi-arabinitol como compuestos antiviricos.
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
US4973602A (en) * 1988-11-03 1990-11-27 G. D. Searle & Co. Antiviral compounds and a method of use thereas
US4894388A (en) 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
EP0389723A1 (fr) * 1989-03-29 1990-10-03 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'alpha-glucosidases
FR2648486B1 (fr) * 1989-06-16 1991-08-30 Gerland Sa Composition pour le traitement antifeutrant de la laine
EP0422307A1 (fr) * 1989-10-10 1991-04-17 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de alpha-glucosidase
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5290948A (en) * 1990-09-17 1994-03-01 Mcneilab, Inc. Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
US5401645A (en) 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
JPH0625157A (ja) 1992-07-13 1994-02-01 Taisho Pharmaceut Co Ltd ポリヒドロキシピロリジン誘導体類およびその製造方法
HUP9901132A2 (hu) * 1995-09-08 1999-07-28 Novo Nordisk A/S 2-Alkilpirrolidinek

Also Published As

Publication number Publication date
JP2000095686A (ja) 2000-04-04
NO982055L (no) 1998-05-06
IL124109A (en) 2001-10-31
CZ120398A3 (cs) 1998-12-16
EP0858335B1 (fr) 2003-03-12
EP1040827A2 (fr) 2000-10-04
AU6785996A (en) 1997-03-27
EP0858335A1 (fr) 1998-08-19
AU724003B2 (en) 2000-09-07
HUP9901132A2 (hu) 1999-07-28
US5854272A (en) 1998-12-29
JPH11503762A (ja) 1999-03-30
CN1202105A (zh) 1998-12-16
DE69626660D1 (en) 2003-04-17
DE69626660T2 (de) 2003-08-21
JP3043430B2 (ja) 2000-05-22
WO1997009040A1 (fr) 1997-03-13
US6451836B1 (en) 2002-09-17
EP1040827A3 (fr) 2000-10-11
EP0884050A1 (fr) 1998-12-16
IL124109A0 (en) 1998-12-06
ATE234092T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
BG102644A (en) Improved concentrated inoculation and infusion solutions for intravasal application
BR9808491A (pt) Compostos calcilìticos
DE59807248D1 (de) Implantatkörper
ES2181168T3 (es) Mezclas solidas a base de sulfonilureas y adyuvantes.
MX9302414A (es) Proceso para la fabricacion de pirrolidinas (s)-3-amino-1- substituidas.
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
ES2172682T3 (es) Preparaciones desodorantes con contenido en quitosano, clorohidrato de aluminio e inhibidores de esterasa.
NO990849D0 (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
PT633928E (pt) Microrganismos processo de preparacao e utilizacao
MXPA04010915A (es) Base y procedimiento de conocimiento de recursos humanos dinamicos.
NO20005548D0 (no) Mykobakterieinhibitorer
TR200103219T2 (tr) Nöropatik ağrının iyileştirilmesinde kullanım için aroil aminoasil piroller
ES2175842T3 (es) Antagonistas de kv2.1.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
IT1280806B1 (it) Procedimento di compressione per segnali elettroencefalografici.
MY140504A (en) Statin-mmp inhibitor combinations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application